Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315166 · ClinicalTrials.gov registry record · NA
Study on Using Radiofrequency to Treat Moderate to Severe Acne
A NA study of Moderate to Severe Acne Vulgaris, sponsored by Pollogen.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06315166 is a NA study of Moderate to Severe Acne Vulgaris that is active but no longer recruiting, run by Pollogen. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06315166, a NA study of Moderate to Severe Acne Vulgaris, is active but no longer recruiting, sponsored by Pollogen.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.
Conditions Studied
Interventions
- DEVICE triLift/Legend Pro+ Fractional RF System
Study Locations (1)
Michigan
- Cosmedic Dermatology (CosmedicDerm) - Grosse Pointe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-23 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315166
The ClinicalTrials.gov registry entry for NCT06315166 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pollogen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which triLift/Legend Pro+ Fractional RF System is the first listed.
NCT06315166 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06315166 about?
NCT06315166 is a clinical study titled "Study on Using Radiofrequency to Treat Moderate to Severe Acne". Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.
What is the current status of trial NCT06315166?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-05-23. Estimated completion is 2027-12.
What conditions does trial NCT06315166 study?
This clinical trial studies the following conditions: Moderate to Severe Acne Vulgaris.
What interventions are being tested in trial NCT06315166?
The interventions under investigation include: triLift/Legend Pro+ Fractional RF System (DEVICE).
Who is sponsoring clinical trial NCT06315166?
This trial is sponsored by Pollogen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315166 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.